{
    "pmcid": "10060843",
    "qa_pairs": {
        "How do some neutralizing antibodies prevent SARS-CoV-2 from entering host cells?": [
            "By sterically hindering the binding of the RBD to ACE2",
            "By enhancing the viral entry process",
            "By targeting the nucleocapsid protein",
            "By binding to the viral RNA"
        ],
        "What advantage do nanobodies have over conventional antibodies in targeting the SARS-CoV-2 spike protein?": [
            "They can bind to unique epitopes inaccessible to conventional antibodies",
            "They have a larger size allowing for more extensive binding",
            "They are derived from human antibodies, making them more effective",
            "They are less stable but more specific"
        ],
        "What is the primary target for neutralizing antibodies in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD) of the S1 subunit",
            "The S2 subunit responsible for membrane fusion",
            "The entire spike protein without specific focus",
            "The nucleocapsid protein of the virus"
        ],
        "What technology is used to screen and identify high-affinity nanobodies against the SARS-CoV-2 spike protein?": [
            "Phage display technology",
            "CRISPR-Cas9 gene editing",
            "Next-generation sequencing",
            "Flow cytometry"
        ],
        "Which domain within the SARS-CoV-2 spike protein is responsible for binding to the human ACE2 receptor?": [
            "The receptor-binding domain (RBD) of the S1 subunit",
            "The N-terminal domain (NTD) of the S1 subunit",
            "The S2 subunit",
            "The membrane fusion domain"
        ]
    }
}